Windlas Biotech IPO: Here's how to check allotment status

NEW DELHI: The initial public offer (IPO) of Windlass Biotech, a manufacturer of pharmaceutical formulations, will finalise the basis of allotment on Wednesday, August 11.

The three-day IPO received bids for 13,77,39,750 shares against 61,36,252 shares on offer, as per NSE data. At the upper limit of the price band, the issue attracted bids worth Rs 6,336 crore against the issue size of Rs 401 crore.

Investors, who had bid for the issue, can check allotment status on the Bombay Stock Exchange (BSE) website:

1) Visit https://www.bseindia.com/investors/appli_check.aspx
2) Under the issue type, click Equity
3) Under the issue name, select Windlas Biotech in the dropbox
4) Write the application number
5) Add the PAN card ID
6) Click on 'I am not a Robot and hit submit.

You can also check the allotment status on the online portal of Link Intime India Private Limited (https://linkintime.co.in/MIPO/Ipoallotment.html), the registrar to the issue. The registrar is a Sebi-registered entity, qualified to act as such and which electronically processes all applications, and carries out the allotment process as per the prospectus.

The registrar is responsible for complying with the timelines for updating the electronic credit of shares to successful applicants, dispatch, and uploading of refunds, and attending to all investor-related queries after the issue is completed.

1) Go to the web portal of Link Intime India Private Limited
2) Select the IPO in dropbox whose name will be populated only if the allotment is finalised
3) You may be required to select either one of the three modes: Application number, Client ID or PAN ID
4) In application type, select between ASBA and non-ASBA
5) Enter the details of the mode you selected in Step 2
6) For security purposes, fill the captcha accurately
7) Hit submit.

Proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant-IV and addition of injectables dosage capability at the facility at Dehradun Plant-II.

It will also be used for funding incremental working capital requirements, repayment/ prepayment of certain borrowings, and general corporate purposes.